Adagio Medical

    Company Information

    Adagio Medical was founded on January 2011. The company is based in Laguna Hills, CA, USA . The number of employees in Adagio Medical is less than 50. Adagio medical is engaged in the research and development of treatments for cardiovascular diseases.

    Here is how Adagio Medical describes itself: "iCLAS Ultra Low Temperature Cryoablation Catheters for Atrial Fibrillation, Atrial Flutter and Ventricular Tachycardia"
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Adagio Medical has received 3 rounds of venture funding. The total funding amount is around $49.1M. Last venture funding round was $42.5M, announced on November, 2020.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Adagio Medical - Blog

                          • Journal of Cardiovascular ElectrophysiologyUltralow temperature cryoablation: Safety and efficacy of preclinical atrial and ventricular lesions

                          • Felix Bourier, MD, Masateru Takigawa, MD, PhD, Anna Lam, MD, Konstantinos Vlachos, MD, F. Daniel Ramirez, MD, MSc, Claire A. Martin, MD, Antonio Frontera, MD, PhD, Takeshi Kitamura, MD, Josselin Duchateau, MD, Thomas Pambrun, MD, Nicolas Derval, MD, Arnaud Denis, MD, Jerry Cox, MD, David Cabrita, MD, Alexander Babkin, PhD, Marion Constantin MA, Pierre Jais MD, Frederic Sacher, MD, PhD, Remi Dubois, MD, PhD, Oliver Bernus, PhD, Michel Haissaguerre, MD, Meleze Hocini, MDThis article is protected by copyright. All rights reserved.The post <p style="font-size:32px; text-align:center;"><strong>Journal of Cardiovascular Electrophysiology</strong></br>Ultralow temperature cryoablation: Safety and efficacy of preclinical atrial and ventricular lesions</p> appeared first on Adagio Medical.
                          • Journal of Cardiovascular ElectrophysiologyUltra-low temperature cryoablation: The coolest innovation EP has been waiting for?

                          • Tom J.R. De Potter, MD, Lucas V.A. Boersma, MD, PhDThis article is protected by copyright. All rights reserved.The post <p style="font-size:32px; text-align:center;"><strong>Journal of Cardiovascular Electrophysiology</strong></br>Ultra-low temperature cryoablation: The coolest innovation EP has been waiting for?</p> appeared first on Adagio Medical.
                          • Adagio Medical Raises $42.5 Million In Series E Financing

                          • LAGUNA HILLS, Calif., Nov. 12, 2020 /PRNewswire/ -- Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced that it has closed a $42.5 million Series E equity financing.  Proceeds from the financing will be used to [...]The post Adagio Medical Raises $42.5 Million In Series E Financing appeared first on Adagio Medical.
                          • Adagio Medical, Inc., reports pre-clinical effectiveness combining their existing ultra-low temperature cryoablation catheter with Pulsed Field Ablation (PFA) in a single Pulsed Field Cryoablation (PFCA) catheter

                          • LAGUNA HILLS, Calif., August 3, 2020 /PRNewswire/ --Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AFib) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced successful pre-clinical results demonstrating their existing cryoablation catheter is also capable of ablating the tissue through pulsed field ablation (PFA) [...]The post Adagio Medical, Inc., reports pre-clinical effectiveness combining their existing ultra-low temperature cryoablation catheter with Pulsed Field Ablation (PFA) in a single Pulsed Field Cryoablation (PFCA) catheter appeared first on Adagio Medical.
                          • Adagio Medical Receives CE Mark Approval for its iCLAS™ Cryoablation System and Prepares for European Commercial Launch

                          • LAGUNA HILLS, Calif., June 1, 2019 /PRNewswire/ --Adagio Medical, Inc., announces that it has received CE Mark approval for its ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) for the endocardial treatment of paroxysmal (PAF) and persistent (PsAF) atrial fibrillation and atrial flutter. "More than half of all atrial fibrillation (AF) patients are diagnosed with PsAF. [...]The post Adagio Medical Receives CE Mark Approval for its iCLAS™ Cryoablation System and Prepares for European Commercial Launch appeared first on Adagio Medical.
                          • Adagio Medical Announces First Patient Enrollment in its iCLAS™ U.S. IDE Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Persistent Atrial Fibrillation

                          • LAGUNA HILLS, Calif., Dec. 16, 2019 /PRNewswire/ -- Adagio Medical, Inc. (Adagio) today announced it has enrolled the first patient in its iCLAS™ Investigational Device Exemption (IDE) trial.  The FDA approved study aims to evaluate the safety and efficacy of Adagio's ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) in the treatment of persistent atrial fibrillation (PsAF).  [...]The post Adagio Medical Announces First Patient Enrollment in its iCLAS™ U.S. IDE Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Persistent Atrial Fibrillation appeared first on Adagio Medical.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *